An Open-Label, Multi-Centre, Randomized, Dose-Escalation, Phase 1b Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281, in Combination With Atezolizumab ± Bevacizumab, Following Obinutuzumab Pre-Treatment, in Patients With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma
This is an open-label, multi-centre, randomized, Phase 1b, adaptive, clinical study to
assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary
therapeutic activity of RO6874281 in participants with unresectable advanced and/or
metastatic RCC. The study will consist of dose-escalation part and extension part.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society